Tirzepatide is usually started at 2.5 mg once weekly and increased gradually in 2.5 mg steps. However, there is no single tirzepatide dose that is right for everyone. The appropriate maintenance dose depends on the product, treatment indication, response and tolerability.
In the United States, tirzepatide is sold as Mounjaro and Zepbound. Although both contain the same active ingredient, their approved uses and some dosing recommendations differ. In the European Union, Mounjaro is authorised for both type 2 diabetes and adult weight management.
This guide explains the current official dosing schedules, how dose escalation works, what to do after a missed dose, and why patients should not increase their dose faster than recommended.
In brief
- The usual starting dose of tirzepatide is 2.5 mg once weekly.
- After four weeks, the dose is normally increased to 5 mg once weekly.
- Further increases are made in 2.5 mg increments after at least four weeks on the current dose.
- The maximum recommended adult dose is generally 15 mg once weekly.
- The 2.5 mg dose is an initiation dose rather than an adult maintenance dose.
- Mounjaro and Zepbound contain the same active ingredient, but approved indications and maintenance-dose recommendations differ.
- A missed dose can generally be taken within 4 days (96 hours). After that, it should be skipped and the normal weekly schedule resumed.
Tirzepatide dosing at a glance
For adults starting tirzepatide, the standard escalation schedule begins with 2.5 mg once weekly. The gradual increase is designed partly to improve gastrointestinal tolerability rather than to get patients to the highest dose as quickly as possible.
| Stage | Weekly tirzepatide dose | Typical timing |
|---|---|---|
| Starting dose | 2.5 mg | Weeks 1–4 |
| First increase | 5 mg | From week 5 |
| Further increase if appropriate | 7.5 mg | After at least 4 weeks on 5 mg |
| Further increase if appropriate | 10 mg | After at least 4 weeks on 7.5 mg |
| Further increase if appropriate | 12.5 mg | After at least 4 weeks on 10 mg |
| Maximum adult dose | 15 mg | After at least 4 weeks on 12.5 mg, if appropriate |
This table shows the possible escalation sequence, not a schedule that every patient must complete. Many patients remain on a lower maintenance dose. Dose selection should reflect the approved indication, treatment response, side effects and the prescribing clinician’s assessment.
Why Mounjaro and Zepbound dosing is not exactly the same
Mounjaro and Zepbound both contain tirzepatide, a medicine that acts at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
That does not make the two brand names interchangeable in every regulatory or clinical context.
In the United States, Mounjaro is used for type 2 diabetes, while Zepbound is approved for chronic weight management in eligible adults and for moderate-to-severe obstructive sleep apnoea in adults with obesity. Approved populations and indications can change as regulators review new evidence.
The situation is different in the European Union. Mounjaro is authorised for type 2 diabetes in adults and patients aged 10 years and older, and for weight management in eligible adults. This is one reason patients should check dosing information for the product and jurisdiction in which they are actually being treated rather than relying on a brand-specific schedule found online.
Mounjaro dosing
For adults, Mounjaro is generally started at 2.5 mg once weekly. After four weeks, the dose is increased to 5 mg once weekly.
If a higher dose is required, the dose can then be increased in 2.5 mg increments after at least four weeks at the current dose. Adult doses therefore progress through the available strengths:
- 2.5 mg once weekly
- 5 mg once weekly
- 7.5 mg once weekly
- 10 mg once weekly
- 12.5 mg once weekly
- 15 mg once weekly
The maximum recommended adult dose is 15 mg once weekly.
For people using Mounjaro for type 2 diabetes, increasing the dose is based on the need for additional glycaemic control as well as tolerability. Patients should not automatically increase the dose simply because four weeks have passed.
Zepbound dosing
Zepbound also starts at 2.5 mg once weekly for four weeks. The dose is then increased to 5 mg once weekly.
If necessary, further increases can be made in 2.5 mg increments after at least four weeks on the current dose.
For weight reduction and long-term weight maintenance, the current US prescribing information identifies 5 mg, 10 mg or 15 mg once weekly as recommended maintenance doses.
For adults being treated for moderate-to-severe obstructive sleep apnoea (OSA) with obesity, the recommended maintenance doses are 10 mg or 15 mg once weekly.
The maximum recommended Zepbound dose is 15 mg once weekly.
Treatment response and tolerability should be considered when selecting a maintenance dose. A higher dose is not automatically a better dose.
Is 2.5 mg of tirzepatide a maintenance dose?
For adults, 2.5 mg is primarily a treatment-initiation dose. It allows the body to become accustomed to tirzepatide before exposure is increased.
For Zepbound, the US prescribing information specifically states that 2.5 mg is not an approved maintenance dose. Mounjaro similarly uses 2.5 mg as the starting dose before the standard increase to 5 mg.
This distinction matters because someone who has just started treatment should not judge the eventual effect of tirzepatide based solely on their first few weeks at 2.5 mg.
How quickly should the tirzepatide dose be increased?
The dose should not normally be increased more frequently than once every four weeks.
After the initial four weeks at 2.5 mg, patients generally move to 5 mg. Subsequent increases, when required, are made in 2.5 mg steps only after at least four weeks at the current dose.
The escalation period is clinically important because gastrointestinal adverse effects such as nausea, diarrhoea and vomiting can occur with tirzepatide and may be more noticeable around dose increases.
If side effects are difficult to tolerate, patients should contact the clinician managing their treatment rather than increasing, reducing or stopping tirzepatide on their own.
Do you have to reach 15 mg?
No. 15 mg is the maximum adult weekly dose, not a target that every patient is expected to reach.
A person may remain on a lower maintenance dose when that dose provides an appropriate treatment response and is well tolerated. The suitable dose depends on why tirzepatide is being prescribed as well as individual response and adverse effects.
This is also why a dose-escalation chart should not be interpreted as a timetable requiring an automatic increase every four weeks.
What happens if you miss a tirzepatide dose?
Current US Mounjaro and Zepbound instructions and current EU Mounjaro information use the same basic missed-dose rule.
- If the missed dose is remembered within 4 days (96 hours), it can generally be administered as soon as possible.
- If more than 4 days have passed, skip the missed dose.
- Take the next dose on the regularly scheduled weekly day.
- Do not take an extra dose to compensate for a dose that has been skipped.
People who have missed multiple doses or have had a longer interruption in treatment should contact their prescriber for advice rather than simply restarting at a previous high dose.
Can you change the day you take tirzepatide?
Yes. Official product information allows the weekly administration day to be changed when necessary, provided there are at least 3 days (72 hours) between two doses.
Once the new day has been established, treatment can continue once weekly on that schedule.
Does tirzepatide have to be taken with food?
No. Tirzepatide is administered once weekly and can be taken at any time of day, with or without meals.
It is injected subcutaneously. Approved injection areas include the abdomen and thigh; the back of the upper arm can also be used when another person gives the injection. Injection sites should be rotated.
What if side effects occur when the dose increases?
Gastrointestinal side effects are among the most common problems associated with tirzepatide. These can include nausea, diarrhoea, vomiting, constipation, abdominal discomfort and reduced appetite.
Symptoms may be more noticeable during dose escalation. A patient experiencing troublesome side effects should discuss them with their healthcare professional before the next increase. Depending on the circumstances, the clinician may decide that remaining at a tolerated dose is more appropriate than continuing escalation.
Persistent vomiting or diarrhoea can also cause dehydration. Patients should seek medical advice if symptoms are severe, persistent or make it difficult to maintain adequate fluid intake.
When should someone seek urgent medical advice?
Tirzepatide has important warnings and is not suitable for everyone. Patients should obtain prompt medical assessment for symptoms that could indicate a serious reaction, including severe or persistent abdominal pain, a serious allergic reaction, or severe and continuing vomiting or diarrhoea.
US prescribing information for Mounjaro and Zepbound carries a boxed warning concerning thyroid C-cell tumours observed in rats. It is not known whether tirzepatide causes medullary thyroid carcinoma in humans. In the US, the medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Patients should use the safety information supplied with their own prescribed product and discuss individual contraindications, interactions and warning symptoms with a qualified healthcare professional.
Tirzepatide dosing in children and adolescents
Dosing requires additional care in younger patients because approvals differ by indication and jurisdiction.
Current EU Mounjaro information includes treatment of type 2 diabetes in children and adolescents aged 10 years and older. Current European product information states that no dose adjustment is required solely on the basis of age, sex, race, ethnicity or body weight for patients aged 10 to under 18 being treated for type 2 diabetes.
However, the European product information advises caution when escalating to 10 mg in children weighing less than 60 kg because safety data are limited.
Tirzepatide is not authorised in the EU for weight management in people under 18.
Paediatric dosing should therefore always follow the prescribing information applicable to the patient’s country, indication and product rather than an adult dose chart found online.
Does kidney or liver impairment change the tirzepatide dose?
Current European Mounjaro product information states that no dose adjustment is required solely because of renal or hepatic impairment. However, experience is limited in patients with severe renal impairment, end-stage renal disease or severe hepatic impairment, and additional clinical caution may be appropriate.
Kidney function can also become clinically relevant if gastrointestinal adverse effects lead to significant dehydration. Patients with kidney disease or substantial vomiting or diarrhoea should discuss this with their healthcare professional.
Mounjaro in the US versus the European Union
One of the easiest sources of confusion around tirzepatide is that the same medicine is marketed within different regulatory frameworks.
In the European Union, Mounjaro is authorised both for type 2 diabetes and for weight management in eligible adults. It is also authorised for type 2 diabetes in patients aged 10 years and older.
In the United States, Mounjaro and Zepbound have distinct brand-specific indications. Zepbound is the tirzepatide brand used for chronic weight management in eligible adults and for moderate-to-severe OSA in adults with obesity.
Patients should therefore avoid assuming that advice referring to “Mounjaro,” “Zepbound” or simply “tirzepatide” applies identically in every country.
Tirzepatide dose FAQ
What is the starting dose of tirzepatide?
The usual starting dose is 2.5 mg injected once weekly for four weeks, followed by 5 mg once weekly.
What is the maximum tirzepatide dose?
The maximum recommended adult dose of Mounjaro or Zepbound is generally 15 mg once weekly. Not every patient needs to reach the maximum dose.
Can you go from 5 mg straight to 10 mg?
The standard escalation schedule uses 2.5 mg increments. That means the usual next step after 5 mg, when an increase is appropriate, is 7.5 mg rather than 10 mg. Patients should not change their prescribed dose without discussing it with their healthcare professional.
How long should you stay on each tirzepatide dose?
Further increases should generally occur only after at least four weeks on the current dose. A patient may remain at an appropriate maintenance dose for considerably longer.
Is 15 mg more effective than 5 mg?
Higher doses can produce greater average treatment effects in some clinical trials, but they may also affect tolerability. Dose selection is not simply a matter of choosing the highest available strength. The appropriate dose depends on indication, response, adverse effects and individual clinical circumstances.
Can you take tirzepatide twice in one week?
Tirzepatide is designed for once-weekly dosing. When changing the administration day, there should be at least 72 hours between doses. Patients should not add an extra dose because they believe the previous dose was ineffective.
What should you do if you miss a dose?
If no more than four days have passed, the missed dose can generally be taken as soon as possible. If more than four days have passed, skip it and take the next dose on the normal scheduled day.
Related MediSearcher guides
- Mounjaro: uses, forms and safety reference
- Zepbound: uses, forms and safety reference
- Ozempic vs Mounjaro comparison
- Wegovy vs Mounjaro comparison
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviews medication guides against current regulatory and primary medical sources. This page distinguishes US and European product information where dosing or approved uses differ.
Last reviewed: 14 October 2026
Sources and verification
This guide was checked against current official prescribing and regulatory information available on 14 October 2026. Because indications and product information can change, patients should also check the current information supplied with their medicine.
- US Mounjaro Prescribing Information — Eli Lilly and Company
- US Zepbound Prescribing Information — Eli Lilly and Company
- Mounjaro EPAR and Product Information — European Medicines Agency
- FDA drug approval information for Mounjaro (tirzepatide) — US Food and Drug Administration
This article is for general informational purposes and does not replace individual medical advice. Tirzepatide is a prescription medicine. Dose selection and dose changes should be discussed with the healthcare professional responsible for treatment.